ArticleBMC cancer2010
Association between TGFBR1*6A and osteosarcoma: a Chinese case-control study.
Article in BMC cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The association of polymorphisms on TGFBR1 and colorectal cancer risk: a meta-analysis.Molecular biology reports · 2012Pooled it
- Association between TGFBR1 polymorphisms and cancer risk: a meta-analysis of 35 case-control studies.PloS one · 2012Pooled it
- Landscape of the immune infiltration and identification of molecular diagnostic markers associated with immune cells in patients with kidney transplantation.Scientific reports · 2024Article
- Whole exome sequencing identified a novelFrontiers in oncology · 2022Article
- Identification of Biomarkers for Predicting Allograft Rejection following Kidney Transplantation Based on the Weighted Gene Coexpression Network Analysis.BioMed research international · 2021Article
- Weighted gene co-expression network analysis revealed key biomarkers associated with the diagnosis of hypertrophic cardiomyopathy.Hereditas · 2020Article
- Identification of key gene modules for human osteosarcoma by co-expression analysis.World journal of surgical oncology · 2018Article
- Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis.Oncotarget · 2018Article
- TGFBR1*6A is a potential modifier of migration and invasion in colorectal cancer cells.Oncology letters · 2018Article
- Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy.Nature reviews. Endocrinology · 2017Review
- Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma.Frontiers in pharmacology · 2017Review
- RNA sequencing of Sleeping Beauty transposon-induced tumors detects transposon-RNA fusions in forward genetic cancer screens.Genome research · 2016Article
- Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies.Critical reviews in oncogenesis · 2015Review
- GRM4 gene polymorphism is associated with susceptibility and prognosis of osteosarcoma in a Chinese Han population.Medical oncology (Northwood, London, England) · 2014Article
- Association of the vascular endothelial growth factor (VEGF) gene single-nucleotide polymorphisms with osteosarcoma susceptibility in a Chinese population.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Genome-wide association study identifies two susceptibility loci for osteosarcoma.Nature genetics · 2013Article
- Endothelin-1 single nucleotide polymorphisms and risk of pulmonary metastatic osteosarcoma.PloS one · 2013Article
- Association of polymorphisms in transforming growth factor-β receptors with susceptibility to gastric cardia adenocarcinoma.Molecular biology reports · 2012Article
- Debate about TGFBR1 and the susceptibility to colorectal cancer.World journal of gastrointestinal oncology · 2012Article
- TGFBR1 signaling and breast cancer.Journal of mammary gland biology and neoplasia · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTGFBR1*6A is a common hypomorphic variant of transforming growth factor beta receptor 1 (TGFBR1). TGFBR1*6A is associated with an increased cancer risk, but the association of this polymorphism with osteosarcoma remains unknown. We have measured the frequency of TGFBR1*6A variants in osteosarcoma cases and controls.
methodsOur case-control study is based on 168 osteosarcoma patients and 168 age- and gender-matched controls. Blood samples were obtained and the TGFBR1*6A variant determined by PCR amplification and DNA sequencing. The odds ratio (OR) and 95% confidence interval (95% CI) for the TGFBR1*6A polymorphism were calculated by unconditional logistic regression, adjusted for both age and gender. Three models - dominant, additive and recessive - were used to analyze the contribution of the TGFBR1*6A variant to osteosarcoma susceptibility.
resultsHeterozygotic and homozygotic TGFBR1*6A variants represented 50.4% and 6.0% of the 168 cases, whereas the controls had 18. 5% and 1.3%, respectively. ORs for homozygosity and heterozygosity of the TGFBR1*6A allele were 4.6 [95% CI, 2.33-7.97] and 2.9 [95% CI, 1.59-5.34] in the additive model. There were significant increases in the TGFBR1*6A variants in osteosarcoma cases compared to control in all 3 models. Further analysis showed that TGFBR1*6A genotypes were not associated with gender, age, or tumor location. However, TGFBR1*6A was significantly associated with less metastasis.
conclusionsTGFBR1*6A, a dominant polymorphism of TGFBR1, is associated with increased susceptibility and metastasis spread of osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.